secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0000950170-25-095460
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

MiNK Therapeutics announces complete remission in testicular cancer and Phase 2 gastric cancer survival data
--------------------------------------------------------------------------------

- Complete and durable remission in metastatic testicular cancer patient after single infusion of agenT-797 plus nivolumab, per Nature's Oncogene publication.
- Phase 2 gastric cancer trial data showed immune activation, tumor infiltration, and survival beyond 12 months in checkpoint-refractory patients.
- Separate case report: 42% tumor reduction and >9 months progression-free survival in gastric cancer patient with single agenT-797 infusion plus nivolumab.
- Phase 2 trial (NCT06251973) actively enrolling with additional readouts expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000095017025095460/0000950170-25-095460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000095017025095460/inkt-20250711.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-095460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer